Navigation Links
Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc.
Date:6/3/2008

ALEXANDRIA. Va., June 3 /PRNewswire/ -- Oxford Finance Corporation and ATEL Ventures, Inc., today announced they have provided a $7.5 million senior secured loan to AxoGen, a privately held, venture-backed life science company.

AxoGen is a leader in the advancement of peripheral nerve repair. Their patented product, AVANCE(TM) Nerve Graft is a biological solution used by surgeons for the repair and regeneration of peripheral nerves.

"Oxford's and ATEL's support will allow us to continue our focused efforts on the AVANCE(TM) Nerve Graft, as well as support a rich pipeline of new products furthering AxoGen's commitment to improve the standard of care for patients with peripheral nerve injuries," said Jamie Grooms, AxoGen chief executive officer and co-founder.

"Oxford is pleased to provide capital to support AxoGen's continuing growth," said J. Alden Philbrick, president and chief executive officer of Oxford Finance Corporation. "Their technology is quite unique and a promising solution for people with peripheral nerve damage."

About Oxford Finance Corporation

Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, is a specialty finance firm providing senior secured loans to public and private life science companies worldwide. For 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1 billion in loans, with lines of credit ranging from $500 thousand to $30 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California and Massachusetts. For more information, visit http://www.oxfordfinance.com.

About ATEL Ventures, Inc.

Since its founding in 1977, San Francisco-based ATEL Capital Group has become the largest private and closely-held independent leasing company in the United States, with approximately $2 billion in asset-secured transactions under management. ATEL Capital formed ATEL Ventures, Inc. to provide working capital and equipment financing term loans to emerging growth companies in information technology, life sciences, specialty retail and alternative energy. For information about ATEL Ventures, contact Steven Rea, executive vice president, or visit their website at http://www.atel.com/ventures.

About AxoGen, Inc.

Based in Alachua, Florida, AxoGen is committed to supporting surgeons in their efforts to improve the standard of care for patients with peripheral nerve injuries by "Bringing the Science of Nerve repair to Life." The company is privately held and has received funding from Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures, Springboard Capital II, LLC, SynoGen, and Emergent Growth Fund.


'/>"/>
SOURCE Oxford Finance Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
2. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
3. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
4. Oxford Finance Corporation and GE Healthcare Financial Services Reaffirm Commitment to Biotech Sector in Europe
5. Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors
6. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
7. Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board
8. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
9. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
10. Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
11. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):